FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4289109311> ?p ?o ?g. }

• W4289109311 endingPage "3740" @default.
• W4289109311 startingPage "3740" @default.
• W4289109311 abstract "Background: Gastric adenocarcinoma (GAC) is highly heterogeneous and closely related to colorectal cancer (CRC) both molecularly and functionally. GAC is currently subtyped using a system developed by TCGA. However, with the emergence of immunotherapies, this system has failed to identify suitable treatment candidates. Methods: Consensus molecular subtypes (CMSs) developed for CRC were used for molecular subtyping in GAC based on public expression cohorts, including TCGA, ACRG, and a cohort of GAC patients treated with the programmed cell death 1 (PD-1) inhibitor pembrolizumab. All aspects of each subtype, including clinical outcome, molecular characteristics, oncogenic pathway activity, and the response to immunotherapy, were fully explored. Results: CMS classification was efficiently applied to GAC. CMS4, characterized by EMT activation, stromal invasion, angiogenesis, and the worst clinical outcomes (median OS 24.2 months), was the predominant subtype (38.8%~44.3%) and an independent prognostic indicator that outperformed classical TCGA subtyping. CMS1 (20.9%~21.5%) displayed hypermutation, low SCNV, immune activation, and best clinical outcomes (median OS > 120 months). CMS3 (17.95%~25.7%) was characterized by overactive metabolism, KRAS mutation, and intermediate outcomes (median OS 85.6 months). CMS2 (14.6%~16.3%) was enriched for WNT and MYC activation, differentiated epithelial characteristics, APC mutation, lack of ARID1A, and intermediate outcomes (median OS 48.7 months). Notably, CMS1 was strongly correlated with immunotherapy biomarkers and favorable for the anti-PD-1 drug pembrolizumab, whereas CMS4 was poorly responsive but became more sensitive after EMT-based stratification. Conclusions: Our study reveals the practical utility of CMS classification for GAC to improve clinical outcomes and identify candidates who will respond to immunotherapy." @default.
• W4289109311 created "2022-08-01" @default.
• W4289109311 creator A5001526770 @default.
• W4289109311 creator A5025912184 @default.
• W4289109311 creator A5031649745 @default.
• W4289109311 creator A5067799719 @default.
• W4289109311 date "2022-07-31" @default.
• W4289109311 modified "2023-10-03" @default.
• W4289109311 title "Consensus Molecular Subtypes Efficiently Classify Gastric Adenocarcinomas and Predict the Response to Anti-PD-1 Immunotherapy" @default.
• W4289109311 cites W1539249527 @default.
• W4289109311 cites W1934094702 @default.
• W4289109311 cites W1976525918 @default.
• W4289109311 cites W1998620046 @default.
• W4289109311 cites W2049397238 @default.
• W4289109311 cites W2056817435 @default.
• W4289109311 cites W2100439220 @default.
• W4289109311 cites W2126547130 @default.
• W4289109311 cites W2141414987 @default.
• W4289109311 cites W2309904337 @default.
• W4289109311 cites W2508743435 @default.
• W4289109311 cites W2533508881 @default.
• W4289109311 cites W2559382297 @default.
• W4289109311 cites W2655262992 @default.
• W4289109311 cites W2737578400 @default.
• W4289109311 cites W2755285110 @default.
• W4289109311 cites W2766488046 @default.
• W4289109311 cites W2770459634 @default.
• W4289109311 cites W2785803176 @default.
• W4289109311 cites W2795622837 @default.
• W4289109311 cites W2803788278 @default.
• W4289109311 cites W2804478743 @default.
• W4289109311 cites W2806832126 @default.
• W4289109311 cites W2884397450 @default.
• W4289109311 cites W2906504824 @default.
• W4289109311 cites W2912993657 @default.
• W4289109311 cites W2943196840 @default.
• W4289109311 cites W2952001873 @default.
• W4289109311 cites W2977488629 @default.
• W4289109311 cites W2987648534 @default.
• W4289109311 cites W3006514782 @default.
• W4289109311 cites W3028304854 @default.
• W4289109311 cites W3029371683 @default.
• W4289109311 cites W3033366394 @default.
• W4289109311 cites W3033624893 @default.
• W4289109311 cites W3033869790 @default.
• W4289109311 cites W3036913810 @default.
• W4289109311 cites W3037215952 @default.
• W4289109311 cites W3043602140 @default.
• W4289109311 cites W3044737312 @default.
• W4289109311 cites W3096720134 @default.
• W4289109311 cites W3098108773 @default.
• W4289109311 cites W3107543057 @default.
• W4289109311 cites W3129551551 @default.
• W4289109311 cites W3145734939 @default.
• W4289109311 cites W3147130602 @default.
• W4289109311 cites W3150329092 @default.
• W4289109311 cites W3165198165 @default.
• W4289109311 cites W4206365402 @default.
• W4289109311 cites W4213389259 @default.
• W4289109311 cites W4246664779 @default.
• W4289109311 cites W4281630256 @default.
• W4289109311 doi "https://doi.org/10.3390/cancers14153740" @default.
• W4289109311 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35954402" @default.
• W4289109311 hasPublicationYear "2022" @default.
• W4289109311 type Work @default.
• W4289109311 citedByCount "1" @default.
• W4289109311 countsByYear W42891093112023 @default.
• W4289109311 crossrefType "journal-article" @default.
• W4289109311 hasAuthorship W4289109311A5001526770 @default.
• W4289109311 hasAuthorship W4289109311A5025912184 @default.
• W4289109311 hasAuthorship W4289109311A5031649745 @default.
• W4289109311 hasAuthorship W4289109311A5067799719 @default.
• W4289109311 hasBestOaLocation W42891093111 @default.
• W4289109311 hasConcept C104317684 @default.
• W4289109311 hasConcept C121608353 @default.
• W4289109311 hasConcept C126322002 @default.
• W4289109311 hasConcept C128526571 @default.
• W4289109311 hasConcept C143998085 @default.
• W4289109311 hasConcept C159654299 @default.
• W4289109311 hasConcept C180754005 @default.
• W4289109311 hasConcept C199360897 @default.
• W4289109311 hasConcept C203014093 @default.
• W4289109311 hasConcept C2777701055 @default.
• W4289109311 hasConcept C2778453870 @default.
• W4289109311 hasConcept C2779767149 @default.
• W4289109311 hasConcept C2780057760 @default.
• W4289109311 hasConcept C2781187634 @default.
• W4289109311 hasConcept C2781273526 @default.
• W4289109311 hasConcept C41008148 @default.
• W4289109311 hasConcept C501734568 @default.
• W4289109311 hasConcept C502942594 @default.
• W4289109311 hasConcept C526805850 @default.
• W4289109311 hasConcept C55493867 @default.
• W4289109311 hasConcept C61320498 @default.
• W4289109311 hasConcept C71924100 @default.
• W4289109311 hasConcept C83852419 @default.
• W4289109311 hasConcept C86803240 @default.
• W4289109311 hasConceptScore W4289109311C104317684 @default.

• next